In 2023, Polygon users are approaching Ethereum, according to Flipside data
According to CryptoPotato, data from blockchain analytics firm Flipside shows that Polygon, a second-layer scaling network, had user numbers close to Ethereum in 2023. That year, Polygon attracted 15.24 million users while Ethereum had 15.4 million users - a difference of about 160 thousand wallets. Flipside defines "acquired" users as those who have made at least two transactions on a specific blockchain, with at least one occurring in 2023. In the first half of 2023, Polygon led in user acquisition but was later overtaken by Ethereum which continued to lead by the end of the year. In January 2023, Polygon reached a significant milestone with an acquired user base of 2.8 million accounting for over 40% of its total for that year. According to Flipside's data, Ethereum maintained its leading position throughout the year and Bitcoin came third with an acquired user base of approximately10.65 million people followed by Solana and Arbitrum completing the top five ranking list .
From aggregated data tracking eight blockchains (including Optimism(OP), Avalanche(AVAX) and Base(BASE)), there were around62 million acquired users altogether.Flipside observed that user acquisition peaked in May but gradually declined afterwards.It is worth noting that Flipside believes the surge in user acquisitions starting from March is related to Silicon Valley Bank's collapse.This event may have weakened confidence in centralized entities prompting people towards decentralized custody alternatives.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear
Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

A recorder hidden in toilet paper exposes OpenAI's long-standing safety issues

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs
AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.